Immunis
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18301 Von Karman Ave, Irvine, California...Website
www.immunisbiomedical.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immunis
Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; the company's technology allows replacement of those factors. The company's product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis' first clinical trial is a Phase 1/2a study of the effectiveness of STEM in treating muscle atrophy, which every person experiences with age.Explore more
Immunis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Immunis had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Immunis has new funding data
Check out if Immunis is spiking on competitors!
Check if Immunis has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Immunis recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Immunis, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Immunis
Product Launch: Get notified when Immunis launches new products
Recommended Actions
Reach out to Masked Content who joined Immunis as Masked Content
Find more new buyers
Compare Similar Companies to Immunis
Compare insights from companies similar to Immunis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunis.
Immunis financials insights
Gather financial insights about Immunis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$10M
2025
Series A
$25M
Immunis Tech Stack
A closer look at the technologies used by Immunis
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Funding
Funding
Event
Events
Immunis News & Media
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group. Founded in 1926, Toray has grown into a highly successful conglomerate known for its commitment to solving pressing global health and environmental challenges. With its production of various advImmunis Discusses with Experts Why the Immune System is the Key to Human Healthspan
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis Inc., a leading biotech in secretome therapeutics addressing age-related diseases and immune dysfunction, is proud to unveil its latest video project entitled “Unlocking Lifelong Vitality: Immunis Aims to Supercharge Our Immune System for a Healthier Future.” This project features insights from world-renowned leaders in human health including Dr. Hans Keirstead, Jane Metcalfe, Dr. Peter Diamandis and Dr. Micah Drummond, who share a visioImmunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Models
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis Inc., a private biotechnology company developing novel secretome therapeutics for age-related diseases and immune dysfunction, announces the peer-reviewed publication of research by Immunis and the University of Utah’s Professor Micah Drummond. The study, published in Aging Cell, is entitled “Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice.” The research e“The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time is Now) with world-renowned longevity innovators who examine the future of aging and human healthspan. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing huma
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Immunis
Sign Up For FreeTo access detailed company insights
Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modu... Read More
